On July 13, the US Food and Drug Administration (FDA) approved novavax's COVID-19 vaccine for emergency use in people 18 and older, making it the fourth vaccine to receive emergency authorization for use in the US. At the same time, the recent transmission of new subtypes of novel coronavirus omicron strains, BA.5 and BA.4, has accelerated in the United States and globally, setting off a new peak of infections.

Novavax is a recombinant protein vaccine. In addition to novavax, Pfizer, Modena and Johnson & Johnson vaccines were previously authorized for emergency use in the United States.

'Available data show that the known and potential benefits of the vaccine in people 18 and older outweigh the known and potential risks,' the FDA said in a statement. Data from an ongoing randomized, double-blind, controlled trial showed that the vaccine was 90.4% effective overall in preventing mild, moderate or severe cases of COVID-19.

Common side effects of the vaccine include pain, redness and swelling at the injection site, fatigue, muscle pain, headache, joint pain, vomiting and fever, the FDA said. Fda Administrator Robert Califf said in a statement that the emergency authorization for novavax increases the number of vaccine options currently available and helps prevent the serious consequences of COVID-19 infection, including hospitalizations and deaths.

Ba.5 has become the dominant strain in the United States, according to the latest data from the Centers for Disease Control and Prevention. In the week ended July 2, BA.5 accounted for about 54% of all confirmed cases nationwide, while BA.4 accounted for about 17%. The number of infections caused by the two new subtypes has continued to rise since mid-May.

Stanley Perlman, a professor of microbiology and immunology at the University of Iowa, told Xinhua that repeated infection rates caused by new subtypes are on the rise, and the proportion of BA.5 infections will continue to increase.

Department of the university of California, Los Angeles, school of public health epidemic Zhang Zuofeng, director of the professor told the Xinhua News Agency reporters in an interview, BA. 5 new subtypes have infectivity, short incubation period, transmission speed, asymptomatic infection ratio is high, after a period of time as people vaccination antibody levels gradually decreased, the breakthrough of the virus infection rate will be higher.

Buy high quality and effective DNA & RNA nucleic acid extraction reagent, lab consumables, automatic nucleic acid extractions, real-time PCR equipment and consumables or rna nucleic acid . Send an email to: info@geneture.com and our professional sales engineer will get back to you within 48 hours.

Overview of market area prospect of rna nucleic acid

By region, the market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa (MEA). North America is further divided into countries such as the United States and Canada. The European region is further divided into The United Kingdom, France, Germany, Italy, Spain, Russia and the rest of Europe. The Asia Pacific region is further subdivided into China, Japan, Korea, India, Australia, Southeast Asia and the rest of Asia Pacific. The Latin America region is further subdivided into Brazil, Mexico and the rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa and the rest of MEA.

Analysis and forecast of the market size of PCR diagnostic industry

Polymerase chain reaction (PCR) is a nucleic acid synthesis technology that uses the principle of DNA double-strand replication to replicate specific DNA fragments in vitro. With this technology, the detection equipment can amplify the target gene in a large number in a short time, expanding the target gene fragment to the order of millions to billions, thus achieving high sensitivity detection. At present, polymerase chain reaction (PCR) diagnosis of infectious diseases such as hepatitis, venereal disease, intestinal respiratory disease and tumor single gene detection is an important application field. In 2020, polymerase chain reaction (PCR) diagnostic technology was identified as the "gold standard" for COVID-19 diagnosis due to its high sensitivity and accuracy.

China's PCR diagnostic market is developing rapidly, with the market size growing rapidly from about RMB 2.37 billion in 2015 to about RMB 5.93 billion in 2019, with a compound annual growth rate of 25.8%. China's PCR industry experienced explosive growth due to the huge demand for testing caused by the outbreak of COVID-19 in 2020, and the market size of China's PCR diagnostic industry exceeded 10 billion yuan in 2020. With the introduction of a large number of PCR diagnostic instruments, the PCR diagnostic industry will enter a new stage of development. It is expected that the PCR diagnostic industry will maintain a double-digit growth rate, and the market size of the PCR diagnostic industry will reach about 23.42 billion yuan in 2030 based on the factory price, and the cagR will reach about 13.3% from 2019 to 2030.

Market Demand of the rna nucleic acid

The DNA/RNA Extraction Kit market and other rna nucleic acids are projected to grow at a CAGR of 8.26% during the forecast period 2022-2027.

The COVID-19 pandemic has impacted the rna nucleic acid market for a short time due to restrictions on different business and research activities for rna nucleic acids. In addition, diagnostic tests for other diseases and medical conditions in hospitals and other clinical diagnostic facilities have been affected as COVID-19 has led to fewer patients taking tests. However, the high rate of COVID-19 infection and research activities are undertaken by major companies in the field of sequencing to expand their understanding of the virus and its origins, as well as molecular diagnostics of the SARS-COV-2 virus, have led to the development and launch of many DNA - and RNA-BASED COVID-19 kits, The kits proved so important that they were in great demand.

Market drivers for the rna nucleic acid

The growth of the DNA/RNA extraction kit market is primarily driven by increased investment in R&D activities in different areas, including molecular diagnostics for different chronic and infectious diseases. For example, the US spent $842 billion on R&D activities in 2020, followed by China at $664 billion, according to the ORGANISATION for Economic Co-operation and Development. Technological advances worldwide, new product launches by major market players, and an increase in cancer cases are also likely to complement the growth of the markets under study.

Other factors, such as increased demand for automation of DNA/RNA extraction technologies, new user-friendly and easy extraction kits, and DNA/RNA for analysis of new diseases causing microorganisms, are expected to drive DNA/RNA growth. RNA Extraction Kit market during the forecast period. Therefore, low awareness and availability of the kit and low market penetration in less developed and developing regions around the world are the major factors limiting the growth of the DNA/RNA extraction kit market.

North America is expected to dominate the global rna nucleic acid market during the forecast period

North America, which holds a major share in the rna nucleic acid market, is expected to show a similar trend during the forecast period, mainly due to the high level of R&D activity in the region and the presence of major market players in the region constantly developing their products for the markets studied.

In the region, the US is expected to take a major share of the DNA/RNA extraction kit market due to heavy investment in R&D by government and private entities, increased demand for rna nucleic acids, and the rising prevalence of chronic diseases.

The rna nucleic acid professional supplier manufacturer -Geneture

Geneture is a professional supplier of Nucleic Acid Extraction Reagent,Automatic Nucleic Acid Extraction,Lab consumables, Real-time PCR, Covid-19 Rapid Test Supplier. Buy high quality and effective DNA & RNA nucleic acid extraction reagent, lab consumables, automatic nucleic acid extractions, real-time PCR equipment and consumables.

Feel free to get a qutoe send an email to: info@geneture.com and our professional sales engineer will get back to you within 48 hours.

Inquiry us